Product Reports Resources Pricing Login Book a demo

Ecopoint Medical

Biotech & Life Sciences · London, United Kingdom · Founded 2018

Fibre optic sensors for cardiovascular diagnostics MoreLess

Echopoint Medical is a medical device company, spun out from University College London (UCL) in 2018, that is developing solutions for cardiovascular diagnostics. The company was founded by a multidisciplinary team of engineers and clinicians: Professor Adrien Desjardins, Dr. Richard Colchester, Professor Ioannis Papakonstantinou, and Dr. Malcolm Finlay, a Consultant Cardiologist at Barts Heart Centre. The founders' journey began with research at UCL, exploring how to integrate fibre optic sensors into minimally invasive devices to provide new sensing and imaging capabilities inside the human body.

The company's flagship product is the iKOr™ microcatheter system. This device uses a thin catheter with a 0.2mm wide fibre optic sensor that measures temperature and pressure to assess blood flow and detect obstructions in coronary arteries. It is specifically designed to address a diagnostic gap in conditions like Ischemia and No Obstructive Coronary Artery Disease (INOCA), which disproportionately affects women and involves problems with the heart's smallest blood vessels (microvasculature) that are difficult to see in standard angiograms. By providing a complete physiological profile of the heart's vessels in real-time, the iKOr system aims to give clinicians more precise data to guide treatment decisions, potentially reducing unnecessary stent procedures and improving outcomes for patients who could be treated with medication.

Echopoint Medical operates in the medical technology market, targeting interventional cardiologists and catheterization labs as its primary clients. The business model centers on the development and commercialization of its proprietary microcatheter, sensor technology, and data interpretation platform. The company has secured significant funding to advance its technology, including a Series A round of £4.2 million ($5.37M) in March 2024, bringing its total funding to approximately $9.74M. This funding, led by investors such as Parkwalk Advisors and the UCL Technology Fund, is supporting the iKOr system through the FDA approval process to enter the US market.

Keywords: cardiovascular diagnostics, fibre optic sensors, microcatheter, coronary artery disease, medical device, interventional cardiology, INOCA, microvascular dysfunction, physiological assessment, cardiac health, UCL spinout, iKOr system, blood flow measurement, pressure sensor, cath lab technology, angina, heart disease diagnosis, minimally invasive, medtech, health equity

Talent graph

Ecopoint Medical's talent

Book a demo to see the people
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

3 investors on Ecopoint Medical's cap table

Sourced from Dealroom's funding and investor records.

Seed 3 investors entered at this stage
Parkwalk Advisors
AlbionVC
UCL Technology Fund

Global footprint

Where Ecopoint Medical has talent and traffic

Workforce by country
3 countries with
team presence
🇬🇧 United Kingdom66.7%
🇳🇱 Netherlands13.3%
🇺🇸 United States13.3%
3 countries shown

Market sentiment

What the market is saying about Ecopoint Medical

An AI-synthesized read of the highest-engagement posts about Ecopoint Medical on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ecopoint Medical on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.